Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products that include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. It also provides spinal implant products comprising cervical, thoracolumbar, and interbody systems for use in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 80 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Phone269-389-2600
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$13.60 billion
Profitability
Miscellaneous
Employees36,000
Next Earnings Date4/23/2019 (Confirmed)
OptionableOptionable
Stryker (NYSE:SYK) Frequently Asked Questions
What is Stryker's stock symbol?
Stryker trades on the New York Stock Exchange (NYSE) under the ticker symbol "SYK."
How often does Stryker pay dividends? What is the dividend yield for Stryker?
Stryker declared a quarterly dividend on Wednesday, February 6th. Shareholders of record on Friday, March 29th will be given a dividend of $0.52 per share on Tuesday, April 30th. This represents a $2.08 annualized dividend and a yield of 1.14%. The ex-dividend date of this dividend is Thursday, March 28th. View Stryker's Dividend History.
How were Stryker's earnings last quarter?
Stryker Co. (NYSE:SYK) released its earnings results on Tuesday, January, 29th. The medical technology company reported $2.18 EPS for the quarter, beating analysts' consensus estimates of $2.15 by $0.03. The medical technology company had revenue of $3.80 billion for the quarter, compared to analysts' expectations of $3.73 billion. Stryker had a net margin of 26.12% and a return on equity of 27.60%. View Stryker's Earnings History.
When is Stryker's next earnings date?
How can I listen to Stryker's earnings call?
Stryker will be holding an earnings conference call on Tuesday, April 23rd at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 8777024565.
What guidance has Stryker issued on next quarter's earnings?
Stryker updated its FY19 earnings guidance on Tuesday, January, 29th. The company provided EPS guidance of $8.00-8.20 for the period, compared to the Thomson Reuters consensus EPS estimate of $8.01. Stryker also updated its FY 2019 guidance to $8.00-8.20 EPS.
What price target have analysts set for SYK?
22 brokerages have issued 1-year target prices for Stryker's stock. Their predictions range from $156.75 to $219.00. On average, they anticipate Stryker's stock price to reach $191.7976 in the next twelve months. This suggests a possible upside of 5.3% from the stock's current price. View Analyst Price Targets for Stryker.
What is the consensus analysts' recommendation for Stryker?
22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Stryker in the last year. There are currently 7 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Stryker.
What are Wall Street analysts saying about Stryker stock?
Here are some recent quotes from research analysts about Stryker stock:
- 1. According to Zacks Investment Research, "Stryker has outperformed the industry in a year. The company continues to gain from its core MedSurg unit which put up a solid show in recent times. Additionally, strength in flagship Mako platform has consistently favored the company. Management is optimistic about the recent K2M acquisition which drove the core Neurotechnology & Spine unit in recent times. Solid international growth also buoys optimism. Expansion in operating margin is a positive while a strong view for 2019 is indicative of brighter prospects ahead. On the flip side, contraction in gross margin raises concern. Additionally, revenues in the last reported quarter were impacted by unfavorable foreign currency movement. Pricing pressure also continues to plague Stryker. Stiff competition in the MedTech space remains a headwind for the company. The stock is overvalued at the moment." (4/12/2019)
- 2. Needham & Company LLC analysts commented, "We attended at its Orthopaedics facility in on 11/8/18. We highlight some of our take-aways from the event below." (11/9/2018)
Has Stryker been receiving favorable news coverage?
Media stories about SYK stock have trended somewhat negative this week, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Stryker earned a news impact score of -1.6 on InfoTrie's scale. They also gave media stories about the medical technology company a news buzz of 5.0 out of 10, meaning that recent news coverage is somewhat likely to have an impact on the stock's share price in the next several days.
Who are some of Stryker's key competitors?
Some companies that are related to Stryker include 3M (MMM), Becton Dickinson and (BDX), Boston Scientific (BSX), Baxter International (BAX), FRESENIUS SE &/S (FSNUY), ResMed (RMD), Teleflex (TFX), ABIOMED (ABMD), DexCom (DXCM), Hill-Rom (HRC), Insulet (PODD), ICU Medical (ICUI), Penumbra (PEN), Integra Lifesciences (IART) and Globus Medical (GMED).
What other stocks do shareholders of Stryker own?
Who are Stryker's key executives?
Stryker's management team includes the folowing people:
- Mr. Kevin A. Lobo, Chairman & CEO (Age 54)
- Mr. Timothy J. Scannell, Pres & COO (Age 54)
- Mr. Glenn S. Boehnlein, VP & CFO (Age 57)
- Mr. Michael D. Hutchinson, VP & Chief Legal Officer (Age 48)
- Mr. Lonny J. Carpenter, Group Pres & Adviser to the CEO (Age 57)
Who are Stryker's major shareholders?
Stryker's stock is owned by a number of of retail and institutional investors. Top institutional investors include Loring Wolcott & Coolidge Fiduciary Advisors LLP MA (0.34%), Fenimore Asset Management Inc. (0.13%), Strs Ohio (0.13%), BTIM Corp. (0.11%), Confluence Investment Management LLC (0.09%) and Retirement Systems of Alabama (0.07%). Company insiders that own Stryker stock include Bijoy Sagar, David Floyd, Glenn S Boehnlein, Graham A Mclean, Howard E Cox Jr, Katherine Ann Owen, Kevin Lobo, Lonny J Carpenter, M Kathryn Fink, Michael Damon Hutchinson, Roch Doliveux, Timothy J Scannell, William E Berry Jr and Yin C Becker. View Institutional Ownership Trends for Stryker.
Which institutional investors are selling Stryker stock?
SYK stock was sold by a variety of institutional investors in the last quarter, including Huntington National Bank, Private Capital Advisors Inc., Strs Ohio, LGT Capital Partners LTD., LaFleur & Godfrey LLC, State of Alaska Department of Revenue, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA and Confluence Investment Management LLC. Company insiders that have sold Stryker company stock in the last year include Bijoy Sagar, Glenn S Boehnlein, Katherine Ann Owen, Kevin Lobo, Lonny J Carpenter, M Kathryn Fink, Michael Damon Hutchinson, Timothy J Scannell and Yin C Becker. View Insider Buying and Selling for Stryker.
Which institutional investors are buying Stryker stock?
SYK stock was acquired by a variety of institutional investors in the last quarter, including Ferguson Wellman Capital Management Inc., Chesley Taft & Associates LLC, Northstar Investment Advisors LLC, Polaris Greystone Financial Group LLC, Pacer Advisors Inc., CWM LLC, Pennsylvania Trust Co and Meeder Asset Management Inc.. View Insider Buying and Selling for Stryker.
How do I buy shares of Stryker?
Shares of SYK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Stryker's stock price today?
One share of SYK stock can currently be purchased for approximately $182.16.
How big of a company is Stryker?
Stryker has a market capitalization of $67.96 billion and generates $13.60 billion in revenue each year. The medical technology company earns $3.55 billion in net income (profit) each year or $7.31 on an earnings per share basis. Stryker employs 36,000 workers across the globe.
What is Stryker's official website?
How can I contact Stryker?
Stryker's mailing address is 2825 AIRVIEW BLVD, KALAMAZOO MI, 49002. The medical technology company can be reached via phone at 269-389-2600 or via email at [email protected]
MarketBeat Community Rating for Stryker (NYSE SYK)
MarketBeat's community ratings are surveys of what our community members think about Stryker and other stocks. Vote "Outperform" if you believe SYK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SYK will underperform the S&P 500 over the long term. You may vote once every thirty days.
